Myriad Genetics’ myRisk Hereditary Cancer is a multi-gene diagnostic test that provides increased sensitivity by analyzing 25 genes associated with eight major cancers, including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma.
Each test report will include a genetic test result, a clinical risk report, and a health care management tool based on professional society guidelines, providing clear and actionable information to improve patient care regardless of whether the patient receives a positive or negative test result.
MyRisk Hereditary Cancer is being launched in a phased approach beginning with an early-access, clinical-experience program for a limited number of medical and scientific thought leaders and followed by an expanded access program later in the year. Myriad will present extensive clinical validity data for the panel at the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC) annual meeting and the San Antonio Breast Cancer Symposium.
Myriad Genetics, 800-469-7423